NRx Pharmaceuticals (NRXP) ThinkEquity Conference 2024 summary

Market overview and unmet needs

• Suicide is a national crisis, with 49,000 deaths in 2022 and millions more at risk annually.

• Bipolar depression patients face especially high suicide risk, with half attempting suicide in their lifetime.

• Current approved treatments for suicidality are limited, with ECT as the only FDA-approved option.

• IV ketamine is gaining traction but lacks FDA approval and insurance reimbursement.

• The total addressable market, including chronic pain, could exceed 70 million people.

Product pipeline and clinical progress

• NRx-100 (IV ketamine) is preparing for NDA filing for suicidal depression, supported by four efficacy studies and manufacturing data.

• NRx-101 (oral D-cycloserine/lurasidone) targets suicidal bipolar depression, showing efficacy in reducing suicidality and akathisia.

• NDA filings for both products are planned for this year, with accelerated approval sought for NRx-101.

• NRx-100 studies include dose-ranging, placebo-controlled, and head-to-head trials against ECT, all showing strong efficacy.

• NRx-101 demonstrated superiority in maintaining depression and suicidality reduction post-ketamine, with a strong patent portfolio extending into the mid-2030s.

Commercial and operational strategy

• Hope Therapeutics is building a national network of clinics for suicidally depressed and PTSD patients, aiming for 30+ clinics in 12–18 months.

• Clinic acquisitions focus on positive EBITDA and revenue, with two LOIs signed in Florida and California.

• Clinics will standardize care, offer advanced therapies, and target a $100 million run rate by end of next year.

• Financing strategy leverages corporate bonds and debt, not biotech equity, to acquire profitable clinics.

• Revenue from clinics will be consolidated, strengthening shareholder equity and potentially generating cash flow.